Logo image of NMRA

NEUMORA THERAPEUTICS INC (NMRA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NMRA - US6409791000 - Common Stock

2.205 USD
-0.02 (-0.68%)
Last: 12/8/2025, 11:30:36 AM
Fundamental Rating

1

NMRA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. The financial health of NMRA is average, but there are quite some concerns on its profitability. NMRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NMRA had negative earnings in the past year.
In the past year NMRA has reported a negative cash flow from operations.
NMRA had negative earnings in each of the past 5 years.
NMRA had a negative operating cash flow in each of the past 5 years.
NMRA Yearly Net Income VS EBIT VS OCF VS FCFNMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of NMRA (-132.88%) is worse than 84.82% of its industry peers.
Looking at the Return On Equity, with a value of -178.79%, NMRA is doing worse than 72.77% of the companies in the same industry.
Industry RankSector Rank
ROA -132.88%
ROE -178.79%
ROIC N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
NMRA Yearly ROA, ROE, ROICNMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

NMRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMRA Yearly Profit, Operating, Gross MarginsNMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

NMRA has more shares outstanding than it did 1 year ago.
NMRA has more shares outstanding than it did 5 years ago.
NMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NMRA Yearly Shares OutstandingNMRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
NMRA Yearly Total Debt VS Total AssetsNMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -7.49, we must say that NMRA is in the distress zone and has some risk of bankruptcy.
NMRA has a Altman-Z score of -7.49. This is in the lower half of the industry: NMRA underperforms 67.02% of its industry peers.
A Debt/Equity ratio of 0.15 indicates that NMRA is not too dependend on debt financing.
NMRA has a Debt to Equity ratio of 0.15. This is comparable to the rest of the industry: NMRA outperforms 47.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -7.49
ROIC/WACCN/A
WACCN/A
NMRA Yearly LT Debt VS Equity VS FCFNMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 6.85 indicates that NMRA has no problem at all paying its short term obligations.
The Current ratio of NMRA (6.85) is better than 70.16% of its industry peers.
A Quick Ratio of 6.85 indicates that NMRA has no problem at all paying its short term obligations.
NMRA has a better Quick ratio (6.85) than 71.20% of its industry peers.
Industry RankSector Rank
Current Ratio 6.85
Quick Ratio 6.85
NMRA Yearly Current Assets VS Current LiabilitesNMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

NMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.99%, which is quite impressive.
EPS 1Y (TTM)22.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NMRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.54% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.67%
EPS Next 2Y13.82%
EPS Next 3Y9.7%
EPS Next 5Y13.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMRA Yearly Revenue VS EstimatesNMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
NMRA Yearly EPS VS EstimatesNMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NMRA. In the last year negative earnings were reported.
Also next year NMRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMRA Price Earnings VS Forward Price EarningsNMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMRA Per share dataNMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.82%
EPS Next 3Y9.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NMRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUMORA THERAPEUTICS INC

NASDAQ:NMRA (12/8/2025, 11:30:36 AM)

2.205

-0.02 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)04-27 2026-04-27/bmo
Inst Owners52.04%
Inst Owner Change-8.84%
Ins Owners5.33%
Ins Owner Change0%
Market Cap363.36M
Revenue(TTM)N/A
Net Income(TTM)-236.30M
Analysts75.71
Price Target9.35 (324.04%)
Short Float %5.19%
Short Ratio3.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.08%
Min EPS beat(2)6%
Max EPS beat(2)12.16%
EPS beat(4)3
Avg EPS beat(4)6.72%
Min EPS beat(4)-10.01%
Max EPS beat(4)18.71%
EPS beat(8)5
Avg EPS beat(8)-0.99%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)30.95%
PT rev (3m)30.95%
EPS NQ rev (1m)4.69%
EPS NQ rev (3m)1.28%
EPS NY rev (1m)-1.96%
EPS NY rev (3m)-1.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.75
P/tB 2.75
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -132.88%
ROE -178.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.49%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.85
Quick Ratio 6.85
Altman-Z -7.49
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1039.1%
Cap/Depr(5y)890.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
EPS Next Y4.67%
EPS Next 2Y13.82%
EPS Next 3Y9.7%
EPS Next 5Y13.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.72%
EBIT Next 3Y14.41%
EBIT Next 5Y7.71%
FCF growth 1Y-9.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.04%
OCF growth 3YN/A
OCF growth 5YN/A

NEUMORA THERAPEUTICS INC / NMRA FAQ

What is the fundamental rating for NMRA stock?

ChartMill assigns a fundamental rating of 1 / 10 to NMRA.


What is the valuation status for NMRA stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUMORA THERAPEUTICS INC (NMRA). This can be considered as Overvalued.


Can you provide the profitability details for NEUMORA THERAPEUTICS INC?

NEUMORA THERAPEUTICS INC (NMRA) has a profitability rating of 0 / 10.


What is the financial health of NEUMORA THERAPEUTICS INC (NMRA) stock?

The financial health rating of NEUMORA THERAPEUTICS INC (NMRA) is 4 / 10.